Back to News
Market Impact: 0.22
Oncolytics Biotech® Announces Positive Preclinical Results Combining Pelareorep with a Pan-RAS Inhibitor in Colorectal Cancer
Source: globenewswire.com
Healthcare & BiotechTechnology & Innovation
Oncolytics reported positive preclinical results for pelareorep combined with a pan-RAS inhibitor in a RAS-driven colorectal cancer model. The data support further development of the combination approach, but remain early-stage and do not yet provide clinical efficacy or commercialization implications.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
ONCY0.72
More News
- Here’s the ‘core economic flaw’ in the AI bull case as stock and bond trades unravel, according to a top economist
- Biotech stocks are surging. How investors can play the new drug innovation boom
- Ukraine says Starlink and Starshield high speed restrictions have been lifted
- Goldman says these top tech stocks have plenty of upside ahead of earnings
- Ukraine says Starlink restored as attacks continue in Russia and Ukraine
- Starlink seems to be working normally again in Ukraine